Abstract Body

HCV continues to be a leading cause of liver disease and hepatocellular carcinoma (HCC), both of which are accelerated in HCV- HIV co-infected patients. The advent of DAA has significantly reduced the rate of HCC, but a large proportion of patients continue to be deprived of this beneficial therapy. Our aim was to determine the barriers to initiation of DAA in co-infected patients.

This retrospective analysis included all patients co-infected with both HCV and HIV, followed at Grady Memorial Hospital between January 2012 and December 2017 but did not receive DAA therapy. We evaluated reasons for not initiating DAA in these patients and looked at patient characteristics including age, sex, race, HCV genotype, cirrhosis, hepatitis B status, HIV control, the presence of other cancers, and social issues including drug abuse and health insurance.

Out of 819 patients co-infected with HIV and HCV, 387(47%) received and 432 (53%) did not receive any DAA therapy. The median age in the untreated group was 56 years, 78% of patients were males and 92% African Americans. HIV was detectable in 3. 7% patients in the treated and 34% in the untreated group (p<0. 00001). As compared to the treated group, the untreated group had 11. 5% patients with active cancer, for which they were receiving therapy (p=. 024), 78% patients with alcohol and/or drug abuse issues (p<0. 00001) and 5% patients with end-stage renal disease (ESRD), on hemodialysis (p=0. 000018). 46% of patients had Medicaid while 23% had no health care coverage. About 40 patients were lost to follow up. Poor HIV control with active drug abuse was the most common reason for withholding DAA therapy accounting for up to 60 % of untreated patients. Active cancer requiring therapy (10%), loss to follow up (10%) and ESRD (5%) were the other major reasons for not receiving therapy. Other reasons included patient non-compliance (3%), intolerable side effects (2%), patient refusal (2%) (Figure 1). In the rest, the reason for non-therapy could not be ascertained. At our center, all patients, irrespective of insurance status received DAA.

53% patients did not receive DAA though health insurance is not a barrier at our center. Poor HIV control and active drug use remain the predominant reasons for not receiving DAA therapy in HCV-HIV co-infected patients. Active cancer and loss of follow up were other major barriers. Thus, control of HIV and its consequent sequelae like cancers and nephropathy remains the biggest challenge in